Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

GONZÁLEZ, JACQUELINE S.; PERUSINI, MARÍA AGUSTINA; BASQUIERA, ANA L.; ALFONSO, GRACIELA; FANTL, DOROTEA; LIMA, WALTER MACEDO; NUCIFORA, ELSA; LAZZARINO, CAROLINA; NOVOA, VIVIANA; DE ANDRADE SILVA, MARCELA CAVALCANTI; LARRIPA, IRENE B.; ROCHA, VANDERSON; ARBELBIDE, JORGE; VELLOSO, ELVIRA D. R. P.; BELLI, CAROLINA B.

ANNALS OF HEMATOLOGY

SPRINGER

Lugar: Berlin; Año: 2021

0939-5555

Knowledge on Chronic Myelomonocytic Leukemia (CMML) patients from Argentineand Brazil is limited. Our series of 280 patients depicted an older age at diagnosis(median 72 years-old), 26% of aberrant karyotypes, a prevalence of myelodysplastic(60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2months for patients in CMML-0 (ref.), 24.7 months for those in CMML-1 (HR=2.0,p=0.001), and 8.8 months for patients in CMML-2 (HR=4.6, p